Merus to Present at BofA Securities 2025 Health Care Conference

Core Insights - Merus N.V. is an oncology company focused on developing innovative full-length multispecific antibodies, known as Biclonics and Triclonics [1][3] - The company will have its CEO, Bill Lundberg, participate in a fireside chat at the BofA Securities 2025 Health Care Conference on May 15, 2025 [1] - The presentation will be available via webcast on the company's Investors page, with an archived version accessible for a limited time post-event [2] Company Overview - Merus specializes in the development of Multiclonics, which are bispecific and trispecific antibody therapeutics [3] - These Multiclonics are produced using industry-standard processes and exhibit characteristics similar to conventional human monoclonal antibodies, including long half-life and low immunogenicity [3] - The company promotes its proprietary terms, Biclonics and Triclonics, as registered trademarks [4]